NEW YORK, May 5, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Viatris Inc. (NASDAQ: VTRS).Shareholders who purchased shares of VTRS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/viatris-inc-loss-submission-form-2/?id=146606&from=4 CLASS PERIOD: August 8, 2024 to February ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Viatris Inc. securities between August 8, 2024, and February 26, 2025, of the June 3, 2025, deadline to become lead plaintiffs in a class action lawsuit [1] Group 1: Class Action Details - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by June 3, 2025, to serve as lead plaintiff [2] - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3] Group 2: Case Background - The lawsuit alleges that during the Class Period, Viatris provided misleading information regarding the failed inspection of its Indore, India facility, including the issuance of an FDA warning letter that affected the shipment of eleven products [4] - Defendants allegedly downplayed the impact of the warning letter as a "minor headwind" while concealing material adverse facts about its financial implications [5] - The lack of disclosure regarding the inspection timeline, remediation efforts, and the financial impact led to investors purchasing Viatris securities at artificially inflated prices, resulting in damages when the true details emerged [5]

Core Viewpoint - A lawsuit has been filed against Viatris Inc. and certain senior executives for potential violations of federal securities laws, stemming from misleading statements regarding the company's operational conditions and the impact of a failed FDA inspection on its financial performance [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Western District of Pennsylvania, titled Quinn v. Viatris Inc., et al., No. 25-cv-466, with investors having until June 3, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Viatris securities [2]. Group 2: Company Background and Allegations - Viatris is a global healthcare company that provides medicines to approximately 1 billion patients across over 165 countries [3]. - The complaint claims that Viatris misrepresented the condition of its facilities, stating they were in "good operating condition" and suitable for their intended purposes, while downplaying the significance of a Warning Letter from the FDA following a failed inspection at its Indore, India facility [3][4]. Group 3: Financial Impact - The failed FDA inspection has had a substantial negative impact on Viatris's financial results, preventing the company from manufacturing and distributing key products, including Lenalidomide [4]. - In its Q4 2024 results released on February 27, 2025, Viatris disclosed that the failed inspection would lower 2025 revenue by approximately $500 million and earnings from operations by approximately $385 million, leading to a stock price decline of about 15% on the day of the announcement [5].

Core Viewpoint - Viatris (VTRS) is set to report its first-quarter 2025 results on May 8, 2025, with revenue estimates at $3.24 billion and earnings at $0.50 per share [1] Group 1: Revenue Performance by Segment - Growth in Developed Markets is expected to be driven by strong new product performance and generics, with revenue estimates at $1.9 billion [2][3] - Emerging Markets are likely to see growth from the expansion of the cardiovascular portfolio in Latin America and key markets like Turkey, India, and Brazil, with revenue estimates at $480 million [4] - Sales in JANZ (Japan, Australia, and New Zealand) are anticipated to be negatively impacted by government price regulations, with revenue estimates at $309 million [5] - Greater China may experience revenue growth due to demand for chronic disease management products, with estimates at $553 million [6] Group 2: Brand and Generic Performance - The brand business constitutes the majority of Viatris' portfolio, benefiting from cardiovascular portfolio expansion in Latin America and strong growth in Europe and Greater China [7] - Operating expenses are expected to rise due to investments in new product launches and R&D progress [7] Group 3: Stock Performance and Earnings History - Viatris' shares have declined by 31.2% over the past year, contrasting with a 1% decline in the industry [8] - The company has a mixed earnings surprise history, beating estimates in two of the last four quarters and missing in the other two, with an average surprise of 1.26% [9] Group 4: Earnings Prediction Model - The current model does not predict an earnings beat for Viatris, as it has a Zacks Rank of 4 (Sell) despite an Earnings ESP of +3.31% [10][11]

NEW YORK, May 2, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Viatris Inc. ("Viatris" or the "Company") (NASDAQ: VTRS) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Viatris investors who were adversely affected by alleged securities fraud between August 8, 2024 and February 26, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2? ...

Core Insights - Nxera Pharma has made significant progress since its transformation from Sosei Heptares, aiming to lead biopharmaceutical innovation in Japan and globally [2][3] - The company anticipates 2025 to be a pivotal year with key data readouts from multiple clinical trials and new studies commencing [3] Operational Highlights - Neurocrine initiated a Phase 3 program for NBI-1117568 targeting schizophrenia, supported by positive Phase 2 data [5] - Nxera assigned rights for cenerimod to Viatris, receiving an upfront payment of US$10 million, with additional milestone and royalty potential [6] - An agreement was signed with Holling Bio-Pharma for the commercialization of daridorexant in Taiwan, with a potential launch in 2026 [6] - Clinical development plans for partnered muscarinic agonists include multiple Phase 2 and Phase 3 studies scheduled for 2025 [6] Financial Highlights - Revenue for Q1 2025 totaled JPY 6,644 million (US$43.5 million), an increase of JPY 2,033 million (US$12.5 million) year-over-year, primarily due to the launch of QUVIVIQ® and an R&D milestone event [11] - R&D expenses rose to JPY 3,808 million (US$25.0 million), reflecting increased investment and the impact of a weaker Yen [11] - Operating loss improved to JPY 2,193 million (US$14.4 million) from JPY 3,076 million (US$20.7 million) in the prior year [11] - Net loss decreased to JPY 760 million (US$5.0 million) from JPY 3,281 million (US$22.1 million) in the previous year [11] - Cash and cash equivalents as of 31 March 2025 were JPY 34,465 million (US$230.0 million), an increase of JPY 2,197 million (US$24.3 million) since the beginning of the year [11] Corporate Developments - New appointments to the Board of Directors include Ms. Naoko Shimura and Ms. Nicola Rabson as External Directors [6] - Mr. Kiyoshi Kaneko was appointed Chief Commercial Officer, and Ms. Mariko Nakafuji was promoted to Chief Legal Officer [11] Pipeline and Strategy - Nxera is advancing over 30 active programs from discovery to late clinical stages, focusing on neurology, metabolic diseases, and immunology [10][12] - The company aims to address major unmet needs in rapidly growing medical areas, leveraging its NxWave™ discovery platform [10][12]

Core Viewpoint - The Gross Law Firm is notifying shareholders of Viatris Inc. regarding a class action lawsuit related to misleading statements about the company's Indore, India facility inspection and its subsequent financial performance [1][3]. Group 1: Allegations and Financial Impact - The class period for the lawsuit is from August 8, 2024, to February 26, 2025 [3]. - The complaint alleges that Viatris misrepresented the significance of a warning letter from the FDA regarding its Indore facility, downplaying it as a "minor headwind" [3]. - Following the announcement of disappointing financial results for Q4 and full fiscal year 2024, Viatris attributed its below-expectation guidance to the financial impact from the Indore facility warning letter and import alert [3]. - On February 27, 2025, Viatris' stock price fell from $11.24 to $9.53, a decline of approximately 15.21% in one day [3]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by June 3, 2025, to potentially be appointed as lead plaintiffs [4]. - Registered shareholders will receive updates through a portfolio monitoring software regarding the case's progress [4]. - Participation in the case incurs no cost or obligation for shareholders [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and illegal business practices [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Viatris Inc. (NASDAQ: VTRS) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Viatris, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/viatris-inc. Investors have until June 3, 2025, to ask the Court to be appointed to lead the case. ...

NEW YORK, May 1, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Viatris Inc. (NASDAQ: VTRS).Shareholders who purchased shares of VTRS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/viatris-inc-loss-submission-form-2/?id=146170&from=4CLASS PERIOD: August 8, 2024 to February 2 ...

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Viatris Inc. ("Viatris" or the "Company") (NASDAQ: VTRS) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Viatris investors who were adversely affected by alleged securities fraud between August 8, 2024 and February 26, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/viatris-inc-lawsuit-submissio ...